These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4749642)

  • 41. Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.
    Over J; Bouma BN; Sixma JJ; Bolhuis PA; Vlooswijk RA
    J Lab Clin Med; 1980 Mar; 95(3):323-34. PubMed ID: 7354239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative protein chemistry studies on Factor VIII concentrates].
    Kienast K; Trobisch H
    Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmapheresis: its value in the management of patients with antibodies to factor VIII.
    Francesconi M; Korninger C; Thaler E; Niessner H; Höcker P; Lechner K
    Haemostasis; 1982; 11(2):79-86. PubMed ID: 6806156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new radioimmunoassay for demonstrating the antibody to hepatitis-B-surface-antigen(HBs-Ag).
    Thamer G; Kommerell B
    Clin Chim Acta; 1975 Jun; 61(3):273-8. PubMed ID: 1149254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood coagulation factor VIII (antihemophilic factor): with comments on von Willebrand's disease and Christmas disease.
    Barrow EM; Graham JB
    Physiol Rev; 1974 Jan; 54(1):23-74. PubMed ID: 4594032
    [No Abstract]   [Full Text] [Related]  

  • 46. Heterogeneity in biological activity of human factor VIII antibodies.
    Koutts J; Meyer D; Rickard K; Stott L; Firkin BG
    Br J Haematol; 1975 Jan; 29(1):99-107. PubMed ID: 1081403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Congenital factor XIII deficiency: studies in an infant and his family].
    Mertner MF
    Monatsschr Kinderheilkd (1902); 1972 Jan; 120(1):28-31. PubMed ID: 5016722
    [No Abstract]   [Full Text] [Related]  

  • 48. A protocol for the preparation of cryoprecipitate and cryodepleted plasma.
    Sparrow RL; Greening DW; Simpson RJ
    Methods Mol Biol; 2011; 728():259-65. PubMed ID: 21468954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of hepatitis B antibody by a single-antibody radioimmunoassay.
    Patil JR; Pert JH
    J Immunol Methods; 1975 Jun; 7(2-3):169-78. PubMed ID: 1141688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood-its derivatives and its problems--factor IX.
    Kasper CK
    Ann N Y Acad Sci; 1975 Jan; 240():172-80. PubMed ID: 1089381
    [No Abstract]   [Full Text] [Related]  

  • 51. Purification of the factor VIII complex.
    Thorell L; Blombäck B
    Thromb Res; 1984 Aug; 35(4):431-50. PubMed ID: 6435279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies on the relationship between factor VIII related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg) by immunoelectrophoresis and autoradiography using 125I anti VIIICAg.
    Davies BL; Furlong RA; Peake IR
    Thromb Res; 1981 Apr 1-15; 22(1-2):87-96. PubMed ID: 6794178
    [No Abstract]   [Full Text] [Related]  

  • 53. The prevalence of hepatitis B surface antigen in commercially prepared plasma products.
    Hoofnagle JH; Gerety RJ; Thiel J; Barker LF
    J Lab Clin Med; 1976 Jul; 88(1):102-13. PubMed ID: 932529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Epidemiology of hepatitis in Swiss hemophiliacs].
    Bütler R; Stampfli K
    Schweiz Med Wochenschr; 1979 Oct; 109(39):1449-53. PubMed ID: 556269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.
    Andersson LO; Forsman N; Huang K; Larsen K; Lundin A; Pavlu B; Sandberg H; Sewerin K; Smart J
    Proc Natl Acad Sci U S A; 1986 May; 83(9):2979-83. PubMed ID: 3085106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Study on the levels of anti-A, anti-B isoagglutinin titer in various kinds of concentrates for hemophilia treatment--with special regard to the manufacturing process of factor VIII concentrate].
    Tomita Y; Inagaki M; Taki M; Miura T; Saito N; Sato R; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Feb; 26(2):166-70. PubMed ID: 3927035
    [No Abstract]   [Full Text] [Related]  

  • 57. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large-scale purification of factor VIII by affinity chromatography: optimization of process parameters.
    te Booy MP; Faber A; de Jonge E; Wolterink EP; Riethorst W; Beugeling T; Bantjes A; Over J; König BW
    J Chromatogr; 1990 Mar; 503(1):103-14. PubMed ID: 2111329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoclonal antibodies to human procoagulant factor VIII.
    Rotblat F; Goodall AH; O'Brien DP; Rawlings E; Middleton S; Tuddenham EG
    J Lab Clin Med; 1983 May; 101(5):736-46. PubMed ID: 6403638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factor VIII, a series of homologous oligomers and a complex of two proteins.
    van Mourik JA; Bouma BN; LaBruyère WT; de Graaf S; Mochtar IA
    Thromb Res; 1974 Jan; 4(1):155-64. PubMed ID: 4208388
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.